Ionis partner Novartis announces pelacarsen Phase 3 trial did not meet primary endpoint
Novartis reported the Lp(a)HORIZON Phase 3 trial for competitor pelacarsen did not meet its primary endpoint of reducing cardiovascular events, while Ionis continues independent commercialization efforts.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day